MEK Inhibitor Therapy in Carcinomas With RAF1 Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell Carcinoma

Christopher R McEvoy; Damien Kee; Owen WJ Prall; Timothy D Clay; Clare Scott; Anastasia Backhouse; Stephen B Fox; Andrew P Fellowes; Huiling Xu

Journal article

MEK Inhibitor Therapy in Carcinomas With RAF1 Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell Carcinoma

Christopher R McEvoy, Damien Kee, Owen WJ Prall, Timothy D Clay, Clare Scott, Anastasia Backhouse, Stephen B Fox, Andrew P Fellowes, Huiling Xu

JCO PRECISION ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019

DOI: 10.1200/PO.19.00159

University of Melbourne Researchers

Timothy Clay Author Medical Education

Clare Scott Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Damien Kee Author Medical Biology (w.e.h.i.)

Stephen Fox Author The Sir Peter Maccallum Department of Oncology

Related Projects (1)

PREPARING AUSTRALIA FOR GENOMIC MEDICINE: A PROPOSAL BY THE AUSTRALIAN GENOMICS HEALTH ALLIANCE

The sequencing of the human genome brings the possibility of more accurate identification of the underlying basis of many diseases. This tec..

Grants

Awarded by Australian Genomic Health Alliance (National Health and Medical Research Council)

Funding Acknowledgements

Supported by Melbourne Genomic Health Alliances and the Australian Genomic Health Alliance (National Health and Medical Research Council Grant No.1113531) and the Stafford Fox Medical Research Foundation for funding the Genomic Matching Treatment for Rare Cancers (NOMINATOR) study.

Citation metrics

3Web of Science

4Scopus

3Dimensions

Keywords

Science & Technology

Oncology

Life Sciences & Biomedicine